CD30-positive Lymphoma
1 clinical trials · Condition
◉ Watch CD30-positive Lymphoma
| Record | Firm | Date |
|---|---|---|
| Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies (NCT02780011) | Eric Bernicker, MD | 2015-12-01 |
Track CD30-positive Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.